Dong Shen, M.D., Ph.D. — Chief executive officer
Dr. Shen graduated with PhD degree from Johns Hopkins University School of Medicine and MD degree from Shanghai Jiao Tong University School of Medicine. Dr. Shen has extensive drug development experience in AstraZeneca and Johnson and Johnson, having led projects across multiple therapeutic areas with high unmet medical need. He has held leadership across early and late programs in the areas of infectious disease, oncology and rare disease. Dr. Shen received numerous awards in the past. He was the recipient of Johnson & Johnson leadership award in 2018 and innovation award in 2017. All his manuscripts have been published at the most influential journals, such as Science and Nature. The total number of his publication citations is over 16,400.
ZHIFENG (STEVEN) LONG, PH.D. — CHIEF SCIENCE OFFICER
Steven received his Ph.D. in Genetics from Leeds University in England in 1987. Steven has 30+years of experience in the pharmaceutical industry. Since 1989 he has held key positions atApptec (now Wuxi Apptec), Genetic Therapy, Sandoz, Novartis, AnGes, Personal Diagnostix, and Sirnaomics. He served as VP for CMC at Sirnaomics in 2018 – 2021 and Chief Development Officer in 2021 – 2023. He was responsible for the successful development of STP707, a novel polypeptide nanoparticle drug product containing siRNAs that is now being studied in the clinics for solid tumors including liver cancer. He also led the manufacturing development of applying microfluidic mixing process in GMP production of STP705 in 2019.
Kevin he, M.D, Ph.D — Chief medical officer (CHINA)
Dr Jiaxi He received his medical degree from Sun Yat-Sen University and Guangzhou Institute of Respiratory Disease in Thoracic Oncology and Respiratory Disease. He was a postdoc research fellow in University of Maryland focusing on nucleic acid delivery system and gene therapy. Dr. He is a certified thoracic surgeon, pulmonologist and oncologist in China with abundant clinical experience. He has published over 60 papers in high quality international journals including JCO, JSO, Lung Cancer, et.al and given oral presentations in various international conferences. He is a reviewer and editor of Frontiers and AME Publication Company. Dr. He was awarded as the most promising youth oncologist in the 2nd “35 under 35” Outstanding Youth Oncologist Talent Competition by Chinese Society of Clinical Oncology in 2018. He is one of the co-founder of RNAimmune and is leading the R&D team of RNAimmune Guangzhou.
Stanley He, MBA — Chief Business Officer
Stanley has over 5 years of diverse experience in the startup and investment space. Prior to joining RNAimmune, Stanley was an Investment Associate at Principle Capital, a boutique private equity firm in Shanghai. Stanley is also an avid individual investor who focuses on publicly-listed biotech companies and seed-stage consumer tech companies. Stanley received his B.S. in Business Administration from Babson College and received his MBA from Georgetown University.
nigel yip, MBA — Chief finance officer
Nigel has 10+ years of transaction experiences in merger & acquisitions, initial public offerings, and private equity. Prior to joining Sirnaomics, Nigel served as a vice president in the Credit Suisse’ investment banking team, and later transferred to Credit Suisse’ private equity team covering growth equity opportunities across healthcare, consumer, and technology sectors in Asia Pacific. In his current role, Nigel manages the overall fundraising process of the group and communication with the banking and investor communities.
